Vaginitis Diagnostic Device Classification Rules
Summary
The Food and Drug Administration (FDA, the Agency, or we) is classifying the device that detects nucleic acid sequences from microorganisms associated with vaginitis and bacterial vaginosis into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the device that detects nucleic acid sequences from microorganisms associated with vaginitis and bacterial vaginosis's classification. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Compliance Requirements
- #1
Design verification and validation must include documentation with a detailed device description of device components; ancillary reagents required but not provided; and explanation of the methodology including primer/probe sequence, design, and rationale for sequence selection.; Design verification and validation must include documentation with information that demonstrates the performance characteristics of the device, including: (A) Limit of Detection; (B) Precision (reproducibility); (C) Analytical specificity; (D) Analytical reactivity (inclusivity); (E) Specimen stability; and (F) Effects of interfering substances.; Design verification and validation must include detailed documentation from a prospective clinical study. As appropriate to the intended use, the prospective clinical study must be performed on an appropriate study population, including women of various ages and ethnicities. The prospective clinical study must compare the device performance to results obtained from well-accepted comparator methods.; Design verification and validation must include detailed documentation for device software, including software applications and hardware-based devices that incorporate software.; The labeling required under § 809.10(b) of this chapter must include a detailed explanation of the interpretation of results and acceptance criteria.; For devices with an intended use that includes detection of nucleic acid sequences from bacteria associated with bacterial vaginosis, labeling must include clinical performance stratified by patient demographics such as race, ethnicity, age, and pregnancy status.; For devices with an intended use that includes detection of nucleic acid sequences from bacteria associated with bacterial vaginosis, labeling must include a summary of device results in an asymptomatic population with demographic characteristics appropriate to the intended use population.; For devices with an intended use that includes detection of either Candida species or bacteria associated with bacterial vaginosis, labeling must include a limitation that Candida species and bacterial compositions associated with bacterial vaginosis can be present as part of normal vaginal flora and results should be considered in conjunction with available clinical information.; This device is subject to premarket notification requirements under section 510(k) of the FD&C Act.; The device must comply with the collections of information in part 860, subpart D, regarding De Novo Classification approved under OMB control number 0910-0844.; The device must comply with the collections of information in 21 CFR part 814, subparts A through E, regarding premarket approval approved under OMB control number 0910-0231.; The device must comply with the collections of information in part 807, subpart E, regarding premarket notification submissions approved under OMB control number 0910-0120.; The device must comply with the collections of information in 21 CFR part 820 regarding quality system regulation approved under OMB control number 0910-0073.; The device must comply with the collections of information in 21 CFR parts 801 and 809 regarding labeling approved under OMB control number 0910-0485.
Market Impacts
Reclassification from class III to class II with special controls reduces regulatory burden and enables market access through 510(k) pathway rather than premarket approval; Establishes first predicate device for nucleic acid sequence detection of microorganisms associated with vaginitis and bacterial vaginosis, enabling other manufacturers to develop substantially equivalent devices; All devices of this type must comply with specific special controls including design verification/validation requirements, clinical study documentation, and specific labeling requirements
Validated Company Impacts
BIO-RAD LABORATORIES, INC.
Bio-Rad's Clinical Diagnostics segment designs, manufactures, and markets test systems and test kits for clinical laboratories, which directly aligns with the rule's focus on manufacturers of diagnostic devices detecting nucleic acid sequences from microorganisms. The company's healthcare and clinical diagnostics business model positions it well within the scope of this FDA regulation for medical devices. The federal rule focuses on medical device manufacturing compliance, design verification, and clinical validation requirements for specific diagnostic devices, while the company's disclosed risk factors exclusively address technology cybersecurity and information system disruptions. There is no overlap between the regulatory compliance requirements of this medical device rule and the company's identified technology infrastructure risks.
DANAHER CORP /DE/
Danaher's Diagnostics segment ($9.8B revenue) provides clinical instruments, consumables, and services for disease diagnosis, directly aligning with the rule's focus on medical devices for detecting nucleic acid sequences from microorganisms. The company's global operations in medical device manufacturing and diagnostic test development would be subject to the FDA's design verification, validation, and labeling requirements for such devices. The federal rule focuses on medical device manufacturing compliance requirements for specific diagnostic tests, while the company's disclosed risks are entirely financial and accounting-related with no mention of medical devices, diagnostics, or FDA regulatory compliance. There is minimal overlap as the rule addresses manufacturing and clinical validation risks that the company has not identified in its risk profile.
Edwards Lifesciences Corp
Edwards Lifesciences focuses on cardiovascular medical devices such as heart valves and monitoring systems, not diagnostic tests for vaginitis or bacterial vaginosis. The company's operations in structural heart and critical care do not involve nucleic acid sequence detection or microbiology diagnostics targeted by this rule. The rule's focus on regulatory approvals, clinical trials, and manufacturing quality directly aligns with the company's identified risk factors. The company has specific risks related to regulatory approvals (delays/failures), clinical trials (adverse effects on approvals), and manufacturing quality problems - all of which are directly addressed by this FDA rule's compliance requirements.
HOLOGIC INC
Hologic operates in the diagnostics segment with a focus on women's health through its GYN Surgical business, which aligns with the rule's target market of vaginitis and bacterial vaginosis diagnostics. The company's medical device development and manufacturing operations would be directly subject to the FDA's design verification, validation, and labeling requirements for nucleic acid sequence detection devices. The rule imposes specific regulatory compliance requirements for medical device manufacturers, particularly those producing nucleic acid-based diagnostic tests for vaginitis and bacterial vaginosis. The company's disclosed risk factors include general regulatory compliance risks but none specifically related to medical device manufacturing, diagnostic testing, or FDA classification requirements, indicating minimal direct risk alignment.
MERIT MEDICAL SYSTEMS INC
Merit Medical Systems primarily manufactures interventional medical devices such as catheters, guidewires, and embolization products, with no evidence of producing in vitro diagnostic devices or nucleic acid detection technologies. The company's business operations focus on cardiovascular, radiology, and endoscopy procedures rather than molecular diagnostics or women's health testing devices targeted by this rule. The rule directly addresses the company's FDA regulatory clearance risk by establishing a clear classification pathway and specific requirements for nucleic acid detection devices, which could reduce delays and uncertainty in product commercialization. Additionally, the design verification and validation requirements align with operational risks related to production processes and quality control.
TELEFLEX INC
Teleflex primarily manufactures single-use medical devices such as catheters, surgical instruments, and vascular access products, which do not involve nucleic acid sequence detection or microbiology diagnostics. The company's business operations focus on procedural and therapeutic devices rather than in vitro diagnostic testing for infectious diseases like vaginitis and bacterial vaginosis. The rule directly impacts the company's regulatory compliance risks by imposing specific FDA requirements for medical device manufacturing and labeling, which aligns with their disclosed 'Healthcare Laws and Regulations' risk. It also affects operational risks related to 'Product Development and Market Acceptance' through design verification/validation and clinical study documentation requirements.